Molecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos, São Paulo, 14784 400, Brazil.
Department of Upper Digestive, Barretos Cancer Hospital, Barretos, Brazil.
Sci Rep. 2021 Oct 18;11(1):20596. doi: 10.1038/s41598-021-00208-7.
Esophageal cancer is an aggressive tumor that has a high rate of incidence and mortality worldwide. It is the 10th most frequent type in Brazil, being squamous cell carcinoma (ESCC) the predominant subtype. There is currently an incessant search to identify the frequently altered genes associated with esophageal squamous cell carcinoma biology that could be druggable. This study aimed to analyze the somatic mutation profile of a large panel of cancer-related genes in Brazilian ESCC. In a series of 46 ESCC diagnoses at Barretos Cancer Hospital, DNA isolated from paired fresh-frozen and blood tissue, a panel of 150 cancer-related genes was analyzed by next-generation sequencing. The genes with the highest frequency of mutations were TP53 (39/46, 84.8%), followed by NOTCH1 (7/46, 15.2%), NFE2L2 (5/46, 10.8%), RB1 (3/46, 6.5%), PTEN (3/46, 6.5%), CDKN2A (3/46, 6.5%), PTCH1 (2/46, 4.3%) and PIK3CA (2/46, 4.3%). There was no significant association between molecular and patients' clinicopathological features. Applying an evolutionary action score of p53 (EAp53), we observed that 14 (35.9%) TP53 mutations were classified as high-risk, yet no association with overall survival was observed. Concluding, this the largest mutation profile of Brazilian ESCC patients, which helps in the elucidation of the major cancer-related genes in this population.
食管癌是一种侵袭性肿瘤,在全球范围内具有较高的发病率和死亡率。它是巴西第 10 常见的癌症类型,以鳞状细胞癌(ESCC)为主。目前,人们一直在不断努力寻找与食管鳞状细胞癌生物学相关的经常发生改变的基因,这些基因可能是可药物治疗的靶点。本研究旨在分析巴西 ESCC 中大量癌症相关基因的体细胞突变谱。在巴雷托斯癌症医院的 46 例 ESCC 诊断系列中,从配对的新鲜冷冻和血液组织中分离出 DNA,通过下一代测序分析了 150 个癌症相关基因的panel。突变频率最高的基因是 TP53(39/46,84.8%),其次是 NOTCH1(7/46,15.2%)、NFE2L2(5/46,10.8%)、RB1(3/46,6.5%)、PTEN(3/46,6.5%)、CDKN2A(3/46,6.5%)、PTCH1(2/46,4.3%)和 PIK3CA(2/46,4.3%)。分子特征与患者的临床病理特征之间没有显著相关性。应用 p53 的进化作用评分(EAp53),我们观察到 14 例(35.9%)TP53 突变被归类为高危,但与总生存无关联。总之,这是巴西 ESCC 患者最大的突变谱,有助于阐明该人群中主要的癌症相关基因。